Tumor Lysis Syndrome under Concurrent Chemoradiation for Rectal Cancer in a Patient with Dihydropyrimidin Deficiency

El Benna Houda, Bousrih Chayma, Rachdi Haifa, Mejri Nesrine, Daoud Nouha, Labidi
Soumaya and Boussen Hamouda

Department of Medical Oncology, Tunis El Manar University, Tunisia

^*Correspondance to: Rachdi Haifa 

 PDF  Full Text Case Report | Open Access

Abstract:

Tumor Lysis Syndrome (TLS) is a major oncological emergency involving metabolic perturbations. TLS is usually observed after aggressive treatment or spontaneously in rapidly growing hematological malignancies and exceptionally in solid cancers. Dihydropyrimidine Dehydrogenase (DPD) is the first enzyme acting in the catabolism of 5-fluorouracil (5FU). Patients with a partial deficiency of this enzyme are at risk for developing a severe 5FU-associated toxicity. We report here a rare case of TLS secondary to DPD deficit in a patient treated with concurrent chemoradiation for a locally advanced rectal cancer.

Keywords:

Cite the Article:

Houda EB, Chayma B, Haifa R, Nesrine M, Nouha D, Soumaya L, et al. Tumor Lysis Syndrome under Concurrent Chemoradiation for Rectal Cancer in a Patient with Dihydropyrimidin Deficiency. Ann Clin Case Rep. 2019; 4: 1689 .